MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia
MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia MYND’s Second
January 12, 2022
MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia MYND’s Second
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013 The majority of patients with traumatic
Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer’s Disease
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Focused on becoming a
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome
MAPS and Wesana Health Resume Negotiations Analysis indicates viability of research pathway for MDMA-assisted therapy
Wesana Completes Filing of PCT Patents for Novel Drug Protocols CHICAGO and TORONTO, Dec. 09,
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test MYND Life Sciences (MYND) began research
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease The Company will be initiating a clinical
DMT and PTSD In honour of Veteran’s Day, we’re sharing the story of how a
Nova Mentis Files Genetic Neuroinflammatory Disease Patent Vancouver, British Columbia – November 9, 2021 – Nova
U.S. FDA Approves Nova Mentis Orphan Drug Application Psilocybin Fragile X Syndrome Treatment Vancouver, British
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome Vancouver, British
Agtech and KRTL Biotech Join Forces to Develop and Distribute Unique CBD and Psilocybin Products
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System Partnership will
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System According to
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease “KET-LID”
Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD Lobe Sciences
Lobe Sciences Announces Data Demonstrating That Its CombinationTherapeutic Candidates are Significantly More Effective ThanMonotherapy in
Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than